Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 4Recurrence 2Paraproteinemias 2Papillomavirus Infections 2Immunoglobulin Light-chain Amyloidosis 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Nodule 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Postoperative Complications 1Pneumonia 1Pancreatic Neoplasms 1Obesity 1Neoplasms, Plasma Cell 1Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Breast Cancer 1Intermittent Fasting 1Hypothyroidism 1Hyperthyroidism 1

Interventions

Dexamethasone 49Melphalan 29Cyclophosphamide 24Bortezomib 23Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5birtamimab 5auricularum 5Whole-Body Irradiation 5Thalidomide 5Mycophenolic Acid 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Busulfan 4sargramostim 3miridesap 3isatuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Immunoglobulin Light-chain Amyloidosis × Clinical Protocols × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡